Tandem Diabetes Care (Nasdaq: TNDM) has named its next president and CEO, as current chief John Sheridan plans to retire at the end of this year. Jeannette Bankes will lead the company starting Nov. 16. Most recently president and CEO of GE HealthCare’s patient care solutions business, Bankes has also served as a senior vice […]
Wall Street Beat
Insulet earnings trounce Q3 estimates as it narrows guidance
Insulet’s (Nasdaq: PODD) third quarter outpaced its own expectations and those of Wall Street, boosted by international sales of its Omnipod 5 tubeless insulin pump. Total revenue reached $842.0 million, for a 19.6% gain over the prior year, topping the company’s previous guidance and analysts’ estimates of $832.6 million. The U.S. haul accounted for $570.4 […]
Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
Dexcom (Nasdaq:DXCM) topped Wall Street’s expectations for third-quarter earnings, and the company nudged up its guidance for the remainder of the year as it looks ahead to a potential Medicare coverage decision that could expand the company’s reach in type 2 diabetes. Revenue reached $1.34 billion for an 11% gain over the prior year. U.S. […]
Abbott sets Libre Duo glucose-ketone sensor US launch for December
After claiming an FDA de novo nod in August, Abbott (NYSE: ABT) said it plans to launch its Libre Duo dual-analyte sensor in the U.S. this December. The roll out of the new continuous glucose monitor, which also tracks ketone levels to safeguard against diabetic ketoacidosis, will come after its international debut set for this […]
MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
Senseonics sees activist investor take a major stake
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]
Embecta Q3 results beat analyst expectations
Julia Rock-Torcivia Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June […]
ICU Medical Q2 results beat analyst expectations, driven by infusion systems
Julia Rock-Torcivia ICU Medical (Nasdaq: ICUI) reported second quarter results that beat Wall Street expectations, upping its full-year guidance. San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June […]
Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]
Dexcom Q2 results beat expectations, lead to increased sales outlook
Dexcom (Nasdaq:DXCM) today reported second-quarter results that came in ahead of the consensus Wall Street forecast. Shares of DXCM rose 2% to $76.02 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three […]
